• Who we are
Multispecific yet truly natural antibodies

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Who we are
Who we are

Long term pharma and biotech professionals with a track record of leading projects from research into the market

Our antibody development roots go deep

Read more
Our focus
Our focus

Multispecific yet natural

Alzheimer’s Disease and Antimicrobial Resistance

Read more
CD47 Dual targeting
Our pipeline

Fully human bi- and multi-specific antibodies for the treatment of Alzheimer’s Disease and Antimicrobial Resistant infections

Safe and selective blockade of CD47 on tumors

Read more
Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

Read more
previous arrow
next arrow

Leadership team

Zugriffe: 9665

Oliver Eckelmann, CEO

Oliver Eckelmann, CEO

discoveric bio group

Oliver is a co-founder of the discoveric bio group and serves as the CEO.

Read more

Jean-Philippe Courade, CSO

Jean-Philippe Courade, CSO

discoveric bio alpha & gamma

Jean-Philippe is a Neuroscientist development specialist and serves as CSO to discoveric bio alpha and discoveric bio gamma.

Read more

Philipp Knechtle, CSO

Philipp Knechtle, CSO

discoveric bio beta

Philipp is an antimicrobial development specialist and serves as CSO to discoveric bio beta.

Read more

Back

TM & © discoveric bio group. All rights reserved.
webdesign byhosted climate friendly